Compare Johnson & Johnson (JNJ) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Palantir Technologies Inc — how do they compare? Johnson & Johnson trades at $248.08 (market cap $598.96B), while Palantir Technologies Inc trades at $133.5 (market cap $323.28B). The key difference: Johnson & Johnson is the larger of the two by market cap, and Johnson & Johnson pays a 2.15% dividend while Palantir Technologies Inc pays none. Which is the better fit depends on your goals.
| JNJ | PLTR | |
|---|---|---|
Market Cap | $598.96B | $323.28B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $207.18 |
52-Week Low | $164.36 | $107.27 |
Enterprise Value | $631.90B | $315.46B |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Palantir (PLTR) trades at $135.63, up 2.46% today, showing strong momentum despite being 35% below its 52-week high. The stock exhibits neutral technical signals with mixed moving averages and oscillators. Fundamentally, the company demonstrates exceptional growth with 2025 revenue of $4.48 billion and net income of $1.63 billion, though valuation metrics remain elevated with a P/E of 148.74 and P/S of 65.12. Recent earnings consistently beat expectations, with Q1 2026 EPS of $0.33 surpassing the $0.2774 forecast.
Palantir's AI software leadership and accelerating revenue growth present compelling long-term potential, but the premium valuation creates significant risk if growth moderates. Analyst consensus leans bullish with a $185.75 price target, though the stock faces headwinds from competitive pressures and market rotation out of high-multiple software names. The company's strong government contracts and commercial expansion provide stability, but investors should weigh rich multiples against execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
